RenovoRx, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 12/100
What the filing says
RenovoRx announced participation in a JonesTrading virtual webinar on August 13, 2026 at 1:30 p.m. ET featuring CEO Shaun Bagai and external oncologists (Dae Won Kim at Moffitt Cancer Center, Ravi Shridhar at AdventHealth Cancer Institute) to discuss the TAMP platform and RenovoCath device. The company reported 2025 full-year RenovoCath sales of approximately $1.1 million and Q1 2026 sales of $563,000. No financial transactions, partnerships, clinical trial results, regulatory approvals, or material business changes were disclosed.
Why this rating
Routine investor relations event announcement; no material business development, financial transaction, or clinical milestone disclosed relative to $26.6M market cap.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.